Admin 3julmthh: Created with researched data

2026-04-14T20:14:40Z

Created with researched data

← Older revision		Revision as of 20:14, 14 April 2026
Line 1:		Line 1:
	{{~~Company~~		{{DISPLAYTITLE:IC Targets}}
	\|name=IC Targets		{{Infobox company
	\|~~location~~=Norway		\| name = IC Targets AS
	\|~~category~~=~~AI Drug Discovery & Genomics~~		\| org_number = 984531524
	\|~~founded~~=N/A		\| founded = 2002-02-16
	\|~~funding~~=~~N/A~~		\| employees = Not disclosed
	\|~~website~~=N/A		\| address = Norway
			\| industry = 72.100 – Biotechnology research
			\| website = https://www.ictargets.com
			\| nht_category = Startup
			\| description = IC Targets (Norwegian Contrasts) is a life science company dedicated to developing manganese-based MRI contrast agents and new methods to improve diagnostic imaging. The company focuses on manganese as an alternative to gadolinium-based contrast agents, addressing concerns about gadolinium deposition in tissues.
			\| notes = Founded 2002 — older than most NHT members. Manganese MRI contrast is an active research area addressing gadolinium safety concerns.
			\| related_companies = [[NordicImagingLab]], [[Hemispherian]], [[Norway Health Tech]]
			\| categories = Norway Health Tech, Startups, Diagnostics, Medical Imaging, Contrast Agents
			\| sources = https://www.ictargets.com; https://data.brreg.no/enhetsregisteret/api/enheter/984531524
	}}		}}

	== ~~What They Do~~ ==		== About ==
	~~Health startup~~

	~~== Funding ==~~		IC Targets AS (Norwegian Contrasts) is a Norwegian life science company developing novel MRI contrast agents based on manganese chemistry. Founded in 2002, making it one of the oldest companies in the NHT cluster.
	~~'''Valuation:''' Not disclosed~~. ~~Norway Health Tech member~~.

	== ~~Revenue~~ ==		== Technology ==
	~~'''Source:''' proff.no (to be researched)~~

	~~== See Also ==~~		The company's core innovation is manganese-based MRI contrast agents. Conventional MRI contrast agents are based on gadolinium, which has raised safety concerns due to deposition in brain tissues and kidneys. Manganese is a naturally occurring mineral (essential trace element) that can serve as an alternative MRI contrast agent, potentially offering improved safety profiles.
	* [[Norway Health Tech]]
	* [[Norway]]
	* [[Companies]]

	[[Category:~~Company~~]]		== Market Need ==
	[[Category:~~Norway~~]]
			Gadolinium-based contrast agents are used in approximately 30-50% of MRI examinations globally. Growing concerns about gadolinium retention in the brain and other tissues have created interest in alternative contrast technologies. A manganese-based agent that maintains diagnostic efficacy while reducing safety concerns would address a significant market need.

			== References ==
			<references/>

			[[Category:Norway Health Tech]]
			[[Category:Startups]]
			[[Category:Diagnostics]]
			[[Category:Medical Imaging]]
			[[Category:Contrast Agents]]

Admin 3julmthh: Created from NHT member research

2026-04-14T18:55:25Z

Created from NHT member research

New page

{{Company
|name=IC Targets
|location=Norway
|category=AI Drug Discovery & Genomics
|founded=N/A
|funding=N/A
|website=N/A
}}

== What They Do ==
Health startup

== Funding ==
'''Valuation:''' Not disclosed. Norway Health Tech member.

== Revenue ==
'''Source:''' proff.no (to be researched)

== See Also ==
* [[Norway Health Tech]]
* [[Norway]]
* [[Companies]]

[[Category:Company]]
[[Category:Norway]]

IC Targets - Revision history

Admin 3julmthh: Created with researched data

Admin 3julmthh: Created from NHT member research